Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann T Farrell

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
The Oncologist|July 19, 2018
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic LeukemiaE Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer PatientsLiang Li, Lian Ma, Sarah J Schrieber, et al.
The Oncologist|April 14, 2018
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaKelly J Norsworthy, Chia-Wen Ko, Jee Eun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
The Oncologist|April 7, 2018
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeRobert Q Le, Liang Li, Weishi Yuan, et al.
Cytometry. Part B, Clinical Cytometry|June 26, 2015
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myelomaNicole J Gormley, Danielle M Turley, Jennifer S Dickey, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual DiseaseEmily Y Jen, Qing Xu, Aaron Schetter, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
The Oncologist|July 19, 2018
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic LeukemiaE Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer PatientsLiang Li, Lian Ma, Sarah J Schrieber, et al.
The Oncologist|April 14, 2018
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaKelly J Norsworthy, Chia-Wen Ko, Jee Eun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 27, 2020
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host diseaseBellinda L King-Kallimanis, Tanya Wroblewski, Virginia Kwitkowski, et al.
The Oncologist|April 7, 2018
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeRobert Q Le, Liang Li, Weishi Yuan, et al.
Cytometry. Part B, Clinical Cytometry|June 26, 2015
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myelomaNicole J Gormley, Danielle M Turley, Jennifer S Dickey, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual DiseaseEmily Y Jen, Qing Xu, Aaron Schetter, et al.
Pageof 6